Yes

Androgen

Control of metastatic breast cancer; management of anemia of renal insufficiency

C-III

X

Carcinoma of breast or prostate, nephrosis, pregnancy and infants, hypersensitivity to any component

Monitor diabetic patients carefully; anabolic steroids may cause peliosis hepatis, liver cell tumors, and blood lipid changes with increased risk of arteriosclerosis; use with caution in elderly patients, they may be at greater risk for prostatic hypertrophy; use with caution in patients with cardiac, renal, or hepatic disease or epilepsy

Male:

Postpubertal:

>10%:

Dermatologic: Acne

Endocrine & metabolic: Gynecomastia

Genitourinary: Bladder irritability, priapism

1% to 10%:

Central nervous system: Insomnia, chills

Endocrine & metabolic: Decreased libido, hepatic dysfunction

Gastrointestinal: Nausea, diarrhea

Genitourinary: Prostatic hypertrophy (elderly)

Hematologic: Iron deficiency anemia, suppression of clotting factors

<1%: Hepatic necrosis, hepatocellular carcinoma

Prepubertal:

>10%:

Dermatologic: Acne

Endocrine & metabolic: Virilism

1% to 10%:

Central nervous system: Chills, insomnia

Dermatologic: Hyperpigmentation

Gastrointestinal: Diarrhea, nausea

Hematologic: Iron deficiency anemia, suppression of clotting

<1%: Hepatocellular carcinoma, necrosis

Female:

>10%: Endocrine & metabolic: Virilism

1% to 10%:

Central nervous system: Chills, insomnia

Endocrine & metabolic: Hypercalcemia

Gastrointestinal: Nausea, diarrhea

Hematologic: Iron deficiency anemia, suppression of clotting factors

Hepatic: Hepatic dysfunction

<1%: Hepatic necrosis, hepatocellular carcinoma

Increased toxicity: Oral anticoagulants, insulin, oral hypoglycemic agents, adrenal steroids, ACTH

Promotes tissue-building processes, increases production of erythropoietin, causes protein anabolism; increases hemoglobin and red blood cell volume

Onset: 3-6 months

Duration: Up to 30 days

Absorption: 77% intramuscularly

Metabolism: In the liver

Elimination: Renal

Deep I.M. (into gluteal muscle):

Adults:

Male:

Breast cancer (phenpropionate): 50-100 mg/week

Anemia of renal insufficiency (decanoate): 100-200 mg/week

Female: 50-100 mg/week

Breast cancer (phenpropionate): 50-100 mg/week

Anemia of renal insufficiency (decanoate): 50-100 mg/week

Inject deeply I.M., preferably into the gluteal muscle

Altered glucose tolerance tests

May cause insomnia

None reported

No information available to require special precautions

No effects or complications reported

This drug can only be given I.M. Diabetics should monitor serum glucose closely and notify prescriber of changes; this medication can alter hypoglycemic requirements. You may experience acne, growth of body hair, loss of libido, impotence, or menstrual irregularity (usually reversible); nausea or vomiting (small frequent meals, frequent mouth care, sucking lozenges, or chewing gum may help); diarrhea (buttermilk, boiled milk, yogurt may help). Report changes in menstrual pattern; enlarged or painful breasts; deepening of voice or unusual growth of body hair; fluid retention (swelling of ankles, feet, or hands, difficulty breathing, or sudden weight gain); unresolved changes in CNS (nervousness, chills, insomnia); change in color of urine or stool; yellowing of eyes or skin; unusual bruising or bleeding; or other adverse reactions. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Do not get pregnant during or for 1 month following therapy. Consult prescriber for instruction on appropriate barrier contraceptive measures. This drug may cause severe fetal defects. Do not breast-feed.

Inject deeply I.M., preferably into the gluteal muscle

Injection, as phenpropionate, in oil: 25 mg/mL (5 mL); 50 mg/mL (2 mL)

Injection, as decanoate, in oil: 50 mg/mL (1 mL, 2 mL); 100 mg/mL (1 mL, 2 mL); 200 mg/mL (1 mL)

Injection, repository, as decanoate: 50 mg/mL (2 mL); 100 mg/mL (2 mL); 200 mg/mL (2 mL)